☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
astellas
Astellas’ Vyloy (Zolbetuximab) Plus Chemotherapy Gains the EC’s Approval for Advanced Gastric and Gastroesophageal Junction Cancer
September 24, 2024
Astellas Reports the US FDA Listing of DIGITIVA to Manage Heart Failure
September 19, 2024
Astellas Begins the P-III Clinical Evaluation of Fezolinetant for Vasomotor Symptoms (VMS) Among Breast Cancer Patients
August 27, 2024
Astellas Collaborates with Poseida Therapeutics to Develop New Allogeneic Cell Therapies in Oncology
May 2, 2024
EMA Granted Extended Approval to Astellas’ XTANDI (Enzalutamide) for Recurrent Early Prostate Cancer Treatment
April 24, 2024
Astellas and Pfizer Report the NMPA’s Acceptance of sBLA for Enfortumab Vedotin Plus Keytruda for Treating 1L Bladder Cancer
March 29, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.